

### **PLA/PLGA nanocarriers designed for tissue engineering application and fabricated by Supercritical Emulsion Extraction**

Erwin Pavel Lamparelli (1), Ida Palazzo (2), Ernesto Reverchon (2), Nicola Maffulli (1),  
Antonietta Santoro (1), Giovanna Della Porta (1,2)

(1) Department of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana” University of Salerno, Via S. Allende 1, 84081 Baronissi (SA), IT.

(2) Department of Industrial Engineering, University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano (SA), IT.

The controlled release of growth factors to promote differentiation of stem cells, during their three-dimensional cultivation into a synthetic scaffold, is a major challenge for modern tissue engineering [1, 2, 3, 4]. Among biopolymers, suitable for protein encapsulation, poly-lactic acid (PLA) and poly-lactic-co-glycolic acid (PLGA) seem most promising, even if the preliminary step for their application in tissue engineering protocols is the kinetic and cytotoxic characterization.

In this study, the microencapsulation of two human growth factors such as growth differentiation factor-5 (hGDF-5) and transforming growth factor  $\beta$ 1 (hTGF- $\beta$ 1), used respectively to induce tenogenic and chondrogenic commitment, was tested using an innovative process based on emulsions and supercritical fluids. Specifically, this technique, known as Supercritical Emulsion Extraction, employs supercritical CO<sub>2</sub> to remove the organic solvent from emulsions, obtaining carriers with suitable sizes and low solvent residual. For this purpose, several double emulsions have been processed, using both conventional solvent evaporation (SE) and the supercritical emulsion extraction (SEE) technology, to establish the better composition in terms of polymer molecular weight, surfactant amount and phases mixing rate in order to develop carriers with a suitable loading.

Carriers cytotoxicity was evaluated with MTT assay both on ovary cell line from hamster (CHO-K1 cells) and human peripheral blood mononuclear cells (hPBMC) in order to obtain more information about the toxic effects of carriers on replicating and terminally differentiated cells.

The results indicated a suitable loading coupled with reduced toxicity for SEE carriers and suggested Supercritical Emulsion Extraction as an effective technology for both micro/nano system formulation and their use for controlled delivery in 3D synthetic matrix.

## References

1. Della Porta, G., Ciardulli, M.C., Maffulli, N., 2018. Microcapsule Technology for Controlled Growth Factor Release in Musculoskeletal Tissue Engineering. *Sports Medicine and Arthroscopy Review* 26.
2. Lamparelli, E.P., Lovecchio, J., Marino, L., Ciardulli, M., Selleri, C., Forsyth, N., Giordano, E., Maffulli, N., Della Porta, G., 2020. Chondrogenic Commitment of human Bone Marrow Mesenchymal Stem Cells cultured under perfusion within a 3D collagen environment releasing hTGF( $\beta$ )1.
3. Ciardulli, M.C., Marino, L., Lovecchio, J., Giordano, E., Forsyth, N.R., Selleri, C., Maffulli, N., Porta, G.D., 2020. Tendon and Cytokine Marker Expression by Human Bone Marrow Mesenchymal Stem Cells in a Hyaluronate/Poly-Lactic-Co-Glycolic Acid (PLGA)/Fibrin Three-Dimensional (3D) Scaffold. *Cells* 9, 1268.
4. Ciardulli MC, Marino L, Lamparelli EP, Guida M, Forsyth NR, Selleri C, Maffulli N, Della Porta G 2020. A study of Tendon Markers expression promoted by Growth Differentiation Factor-5 on Human-Mesenchymal Stem Cells isolated from Bone Marrow and Umbilical Cord *International Journal Molecular Sci*, 2020, 21(16), 5905
5. Della Porta, G., Reverchon, E., Maffulli, N., 2017. Biomaterials and Supercritical Fluid Technologies: Which Perspectives to Fabricate Artificial Extracellular Matrix? *Current Pharmaceutical Design* 23, 3759-3771.
6. Palazzo I, Lamparelli EP, Ciardulli MC, Scala P, Maffulli N, Reverchon E, Santoro A, Della Porta G 2020. PLA/PLGA carriers designed for the Growth Factors sustained delivery by Supercritical Emulsion Extraction: size engineering, release profiles study and cytotoxicity evaluation. *International Journal of Pharmaceutics*, in press.

Dr. Erwin Pavel Lamparelli

PhD Student in Translational Medicine

Department of Medicine, Surgery and Dentistry

“Scuola Medica Salernitana”

University of Salerno

Via S. Allende 84081, Baronissi (SA), Italy

Tel: +39 089 96 5223

Mobile: +39 3899911068

E-mail: elamparelli@unisa.it